Natera, Inc. (NTRA) Rating Lowered to Strong Sell at ValuEngine

Natera, Inc. (NASDAQ:NTRA) was downgraded by research analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research report issued on Monday, July 24th.

NTRA has been the topic of a number of other reports. Zacks Investment Research lowered shares of Natera from a “buy” rating to a “hold” rating in a research note on Thursday, May 11th. Canaccord Genuity lifted their target price on shares of Natera from $14.00 to $16.00 and gave the company a “buy” rating in a report on Wednesday, May 10th. Four equities research analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $14.45.

Natera (NASDAQ NTRA) traded up 5.04% on Monday, reaching $10.62. The company’s stock had a trading volume of 278,269 shares. Natera has a one year low of $7.35 and a one year high of $12.95. The company’s market capitalization is $565.23 million. The firm has a 50-day moving average of $9.97 and a 200-day moving average of $9.55.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Tuesday, August 8th. The medical research company reported ($0.52) EPS for the quarter, meeting analysts’ consensus estimates of ($0.52). The company had revenue of $53.60 million for the quarter, compared to analyst estimates of $50.57 million. Natera had a negative net margin of 62.64% and a negative return on equity of 137.46%. Natera’s quarterly revenue was up 3.1% on a year-over-year basis. During the same period in the previous year, the business posted ($0.46) earnings per share. Analysts predict that Natera will post ($2.08) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Natera, Inc. (NTRA) Rating Lowered to Strong Sell at ValuEngine” was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The correct version of this article can be accessed at

Institutional investors have recently made changes to their positions in the company. GSA Capital Partners LLP purchased a new position in Natera during the fourth quarter worth $121,000. Russell Investments Group Ltd. purchased a new position in Natera during the fourth quarter worth $130,000. Virtu KCG Holdings LLC purchased a new position in Natera during the second quarter worth $126,000. Los Angeles Capital Management & Equity Research Inc. purchased a new position in Natera during the second quarter worth $151,000. Finally, American International Group Inc. raised its position in shares of Natera by 7.1% in the first quarter. American International Group Inc. now owns 16,065 shares of the medical research company’s stock valued at $142,000 after buying an additional 1,068 shares during the period. Institutional investors own 59.74% of the company’s stock.

About Natera

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Natera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply